發(fā)布時(shí)間：2018-01-14 10:23

  本文關(guān)鍵詞：以雷貝拉唑?yàn)榛A(chǔ)的不同療程三聯(lián)療法治療H.pylori感染療效Meta分析　出處：《重慶醫(yī)科大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 雷貝拉唑 三聯(lián)療法 H.pylori 療程 meta分析

【摘要】：目的:對(duì)以雷貝拉唑?yàn)榛A(chǔ)的三聯(lián)療法根治H.pylori感染7d、10d、14d療效進(jìn)行meta分析,以客觀評(píng)價(jià)其療效。方法:計(jì)算機(jī)檢索維普數(shù)據(jù)庫(kù)、萬方數(shù)據(jù)庫(kù)、中國(guó)知網(wǎng)數(shù)據(jù)庫(kù)(CNKI)、PubMed數(shù)據(jù)庫(kù),查找以雷貝拉唑?yàn)榛A(chǔ)的不同療程三聯(lián)療法治療H.pylori感染的相關(guān)文獻(xiàn),運(yùn)用Review Manager5.2軟件對(duì)文獻(xiàn)數(shù)據(jù)進(jìn)行分析。結(jié)果:以雷貝拉唑?yàn)榛A(chǔ)的三聯(lián)療法在H.pylori根除率方面,10d和14d療程效果優(yōu)于7d療程,差異具有統(tǒng)計(jì)學(xué)意義(7d vs 10d:OR0.72,95%CI 0.53~0.96,P=0.03;7d vs 14d:OR 0.49,95%CI0.31~0.79,P=0.003),但10d和14d療程差異無統(tǒng)計(jì)學(xué)意義(OR 0.79,95%CI 0.47~1.34,P=0.39);在不良反應(yīng)發(fā)生率方面,7d、10d、14d三個(gè)療程分別兩兩組間對(duì)比,差異均無統(tǒng)計(jì)學(xué)意義(7d vs 10d:OR1.05,95%CI 0.75~1.47,P=0.78;7d vs 14d:OR 0.80,95%CI0.32~2.00,P=0.63;10d vs 14d:OR 0.82,95%CI 0.45~1.50,P=0.53);在臨床癥狀緩解率方面,上述各組間對(duì)比亦無統(tǒng)計(jì)學(xué)證據(jù)支持何種療程更加有效(7d vs 10d:OR 0.79,95%CI 0.31~2.04,P=0.63;7d vs 14d:OR 0.72,,95%CI 0.26~2.00,P=0.53;10d vs 14d:OR 0.92,95%CI0.32~2.63,P=0.87)。結(jié)論:在以雷貝拉唑?yàn)榛A(chǔ)的三聯(lián)療法治療H.pylori感染時(shí),10d與14d療程效果優(yōu)于7d療程,但10d與14d療程間無統(tǒng)計(jì)學(xué)差異。因此,結(jié)合患者經(jīng)濟(jì)負(fù)擔(dān)及依從性考慮,建議用藥10d則可達(dá)到治療目的,但這仍需更多大樣本臨床隨機(jī)對(duì)照研究進(jìn)一步證實(shí)。
[Abstract]:Objective: to analyze the efficacy of triple therapy based on rabeprazole in the treatment of H.pylori infection for 10 days and 14 days. Methods: the database of Weip, Wanfang and CNKI / PubMed were searched by computer. To find the literature on the treatment of H.pylori infection with different courses of triple therapy based on rabeprazole. Review Manager5.2 software was used to analyze the literature data. Results: triple therapy based on rabeprazole was used in H. pylori eradication rate. The therapeutic effect of 10d and 14d was better than that of 7d. The difference was statistically significant (7d vs 10d OR0.72N). 7 days vs 14 d OR: 0.49% 95% CI 0.31 ~ 0.79%, but there was no significant difference between 10 days and 14 days course of treatment (OR 0.79). 95 CI 0.47 ~ 1.34 ~ 0.39%; There were no significant differences in the incidence of adverse reactions between the two groups for 7 days or 10 days or 14 days, and there was no significant difference between the two groups (7 days vs 10 d OR 1.05). 95 CI 0.75 ~ 1.47 ~ 0.78; 7 days vs 14 days OR 0.80 / 95 / CI 0.32 / 2.00 / 0.63; 10 days vs 14 days OR 0.8295 / CI 0.45 1.50 / 0.53; In the clinical symptom remission rate, there is no statistical evidence between the above groups to support which course of treatment is more effective 7 days vs 10 d: OR 0.79 95 CI 0.31 鹵2.04. P0. 63; 7 days vs 14 days OR 0.72 / 95 CI 0.26 / 2.00 / 0.53; 10d vs 14dOR 0.9295 CI 0.32 / 2.63. Conclusion: in the treatment of H.pylori infection based on rabeprazole, the therapeutic effect of 10 days and 14 days is better than that of 7 days. However, there was no statistical difference between 10 days and 14 days of treatment. Therefore, considering the financial burden and compliance of the patients, it was suggested that 10 days of medication could achieve the purpose of treatment. But this still needs to be further confirmed by a large sample of clinical randomized controlled studies.
【學(xué)位授予單位】：重慶醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R573

【參考文獻(xiàn)】

相關(guān)期刊論文 前8條

1 Fatih Ermis;Elif Senocak Tasci;;Current Helicobacter pylori treatment in 2014[J];World Journal of Methodology;2015年02期

2 Florian Anderl;Markus Gerhard;;Helicobacter pylori vaccination:Is there a path to protection?[J];World Journal of Gastroenterology;2014年34期

3 Jun Heo;Seong Woo Jeon;;Optimal treatment strategy for Helicobacter pylori:Era of antibiotic resistance[J];World Journal of Gastroenterology;2014年19期

4 Chang Seok Bang;Gwang Ho Baik;;Attempts to enhance the eradication rate of helicobacter pylori infection[J];World Journal of Gastroenterology;2014年18期

5 Jyh-Chin Yang;Chien-Wei Lu;Chun-Jung Lin;;Treatment of Helicobacter pylori infection:Current status and future concepts[J];World Journal of Gastroenterology;2014年18期

6 Han-Yi Song;Yan Li;;Can eradication rate of gastric Helicobacter pylori be improved by killing oral Helicobacter pylori ?[J];World Journal of Gastroenterology;2013年39期

7 Hyuk Soon Choi;Hoon Jai Chun;Sang Hoon Park;Bora Keum;Yeon Seok Seo;Yong Sik Kim;Yoon-Tae Jeen;Soon Ho Um;Hong Sik Lee;Chang Duck Kim;Ho Sang Ryu;;Comparison of sequential and 7-,10-,14-d triple therapy for Helicobacter pylori infection[J];World Journal of Gastroenterology;2012年19期

8 Alexander C Ford;Peter Malfertheiner;Monique Giguère;José Santana;Mostafizur Khan;Paul Moayyedi;;Adverse events with bismuth salts for Helicobacter pylori eradication:Systematic review and meta-analysis[J];World Journal of Gastroenterology;2008年48期

，

本文編號(hào)：1423171